ApoRx Biopharmaceuticals
Targeted Protein Degradation Drug Discovery
Company Overview
Snapshot
Founded in January 2021 by Avishai Levy, Omri Erez, Philippe Nakache, and Orna Harel, ApoRx Biopharmaceuticals operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on drug discovery.
Business overview
ApoRx Biopharmaceuticals is a drug-discovery company specializing in the identification, design, characterization, and development of small proteolysis-targeting molecules. Its core technology, the Aperion library, is a proprietary collection of RING E3 ligase binders designed to leverage the intracellular ubiquitin-proteasome machinery for targeted protein degradation. The company aims to degrade and destroy unwanted proteins implicated in cancer and other indications, serving the pharmaceutical and biotechnology sectors within the Health Tech & Life Sciences market.
Log in to access full profile ›Company Intelligence Q&A
- What is ApoRx Biopharmaceuticals' primary focus?
- ApoRx Biopharmaceuticals focuses on targeted protein degradation drug discovery, specifically the discovery, design, characterization, and development of small molecules against disease-causing proteins in cancer and other indications.
- What is the core technology utilized by ApoRx Biopharmaceuticals?
- The core of ApoRx Biopharmaceuticals' technology is the Aperion library, a proprietary focus library of RING E3 ligase binders. This technology is designed to harness the intracellular ubiquitin-proteasome machinery for targeted protein degradation.
- When was ApoRx Biopharmaceuticals founded?
- ApoRx Biopharmaceuticals was founded in January 2021.
- Who are the founders of ApoRx Biopharmaceuticals?
- ApoRx Biopharmaceuticals was founded by Avishai Levy, Omri Erez, Philippe Nakache, and Orna Harel.
- What is ApoRx Biopharmaceuticals' current stage of development?
- ApoRx Biopharmaceuticals is currently in the Pre-Funding stage, with its products in the R&D phase.